



Photo: Eric Bond/EGPAF, 2019



**Elizabeth Glaser  
Pediatric AIDS Foundation**  
Fighting for an AIDS-free generation

## THE KENYA PROGRAM

Working with Women, Children, and Families to End Pediatric AIDS

### THE ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION IN KENYA

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a proven leader in the global fight to end HIV and AIDS, advocating for children to live full and healthy lives into adulthood. Founded over 30 years ago through a mothers determination, EGPAF is committed to a comprehensive response to HIV through research, advocacy, strengthening of local health care systems and growing the capacities of governments and communities in the world's most affected regions to respond to urgent needs.

For the past 20 years, EGPAF has worked with the Kenyan government and communities to provide HIV, AIDS and TB prevention, care, and treatment services for children, adolescents and adults. To achieve this, EGPAF collaborates with multiple partners, including Kenya's Ministry of Health, to provide essential technical and organizational capacity-building assistance to community-based organizations and health facilities throughout supported regions.

### KEY PROGRAM ACCOMPLISHMENTS\*\*

Currently, EGPAF-Kenya is supporting:



HIV treatment to **over 6,400 babies**



Antiretroviral therapy to **nearly 86,000 adults**



PMTCT services to **over 5,000 pregnant women**




HIV testing services to **over 390,000 individuals**

### COUNTRY PROFILE\*

Population	52,573,973
Number of people living with HIV	1,500,000
Adult (15-49 years of age) HIV prevalence	4.5%
HIV prevalence among women (15 years and older)	6.6%
Number of children (0-14 years of age) living with HIV	110,000
New HIV infections (15 years of age and older) (annual)	42,000
AIDS-related deaths in 2019	21,000
Proportion of people aware of their HIV status, and actively enrolled on ART	90%

### EGPAF-KENYA PROGRAM GEOGRAPHIC COVERAGE



\* Sources: Joint United Nations Programme on HIV and AIDS (UNAIDS), Côte d'Ivoire HIV and AIDS estimates (2020); World Bank, Côte d'Ivoire, population estimates (2020)

\*\* EGPAF data as of January 2020

## PROGRAM IMPLEMENTATION

### Timiza 90 (2016-2021)

The U.S. Centers for Disease Control and Prevention (CDC)-funded Timiza 90 project supports the implementation and expansion of comprehensive HIV prevention, care and treatment programs to bring Kenya closer to achieving UNAIDS 95-95-95 (ensure 95% of people living with HIV knowing their HIV status; 95% of people who know their status on treatment; and 95% of people on treatment with suppressed viral loads by 2030). Through Timiza 90, EGPAF provides comprehensive HIV prevention and treatment services, laboratory systems strengthening, voluntary medical male circumcision, comprehensive HIV services to key populations, including orphans and vulnerable children, to Homa Bay County. EGPAF works alongside the Ministry of Health and civil society organizations to accomplish this.

### Catalyzing Pediatric TB innovations (CaP TB) Project (2017-2021)

This Unitaid-funded project aims to improve TB screening in children, and accelerate access to TB diagnosis and treatments for both active and latent pediatric TB. This project will bring new child-friendly TB drug formulations and improved diagnostic technology to ten countries, including Kenya.

### Technical Assistance To Community-Based Organizations (2011-present):

EGPAF collaborates with ViiV Healthcare's Positive Action for Children's Fund (PACF) to strengthen the technical and institutional capacity of community-based organizations (CBO) to further their efforts to prevent mother-to-child HIV transmission (PMTCT). The project seeks to bolster community engagement and involvement of service providers and beneficiaries in HIV prevention, care, and treatment services, specifically in PMTCT programs. The project's primary objective is to empower CBO to engage with their local communities and national health systems to overcome obstacles to quality health care-enhancing CBO's abilities to achieve measurable and sustainable results in their respective programs.

### The Red Carpet Adolescent Health Program (2017-2021)

This ViiV Healthcare Positive Action for Adolescents-funded project aims to improve the long-term health outcomes of adolescents (ages 10-19) and young adults (ages 20-24) living with HIV in Homabay and Turkana counties. The project promotes meaningful involvement of adolescents and young people in HIV prevention, care and treatment programs, while increasing capacity of health care workers in the provision of these services. The project also support schools to be HIV responsive - strengthening bidirectional referrals between health facilities and educational environments.

### The New Horizons Advancing Pediatric and Adolescent HIV Treatment Collaborative Initiative (2014-present)

In response to limited availability of second- and third-line pediatric and adolescent treatment options, Johnson & Johnson, EGPAF, and the Partnership for Supply Chain Management launched New Horizons, which aims to improve ART service delivery for children; confront challenges faced by adolescents around disclosure, adherence, and psychosocial support; and increase access to third-line ART for children and adolescents failing second-line treatment. This project also works to build capacity of health workers and regional technical working groups to provide second- and third-line ART to pediatric and adolescent clients.

### Pediatric Antiretroviral Treatment Formulation Optimization (2019-2021)

This DNDi-supported project will streamline and accelerate use of new, child-friendly ART formulations. EGPAF will focus on the development of new tools for improved control of pediatric HIV and support increased uptake of solid lopinavir/ritonavir, while preparing for introduction of dispersible dolutegravir formulations in Kenya, Tanzania and Uganda.

### Tailored Technical Assistance to Enhance Pediatric and Adolescent HIV Programming (2020-2021)

In collaboration with and through the investment of the ELMA Foundation, EGPAF collaborates with the Kenyan National AIDS and STI Control Programme to provide responsive and tailored pediatric and adolescent HIV technical assistance. Leveraging our existing operational footprint and expertise, this project provides

rapid technical assistance to expand testing and treatment among children and adolescents. The ultimate goal: respond to critical gaps in pediatric and adolescent HIV services.

## ADVOCACY

EGPAF-Kenya participates in national HIV and AIDS technical advisory committees for PMTCT, adult and pediatric treatment, HIV prevention, and monitoring and evaluation. EGPAF is a member of the technical advisory team that supports the national steering committee for elimination of mother-to-child HIV transmission and the First Lady's Beyond Zero campaign that advocates for programs to reduce maternal and infant mortality rates in Kenya. EGPAF supports the Kenyan government to develop policies, guidelines, and health worker training curricula that enhance the scale-up of national HIV and AIDS programs through its involvement in HIV and TB technical working groups.

## RESEARCH

**Evaluation of the Red Carpet Program for Adolescents and Youth aged 15-24 in Homa Bay and Turkana Counties:** This study is evaluating the impact of the Red Carpet program on linkage to and retention in care, at 3, 6 and 12 months, among adolescents and youth (15-2 in Homa Bay and Turkana Counties). A sub-study component is also under analysis: to evaluate self-reported experiences of Red Carpet program service recipients.

**Evaluation of Program Effectiveness Using Routine Data:** Routinely collected program data are evaluated to improve HIV program implementation and program policy decision-making.

**Evaluation of Enhanced Adherence Counselling (EAC) as a Strategy to Optimize Adherence, Retention and Viral suppression among Children and Adolescents, in Homa Bay** A mixed methods study to evaluate clinical outcomes viral suppression, adherence and retention among children and adolescents who receive the EAC package after suspected treatment failure, and after switch to second and third line.

**Evaluation of the CaP TB, a Pre- and Post-Implementation Assessment:** Aims to assess the CaP TB project's clinical outcomes and service delivery.

**Integrating Pediatric TB into Child Health Care Services in Africa:** The cluster-randomized stepped wedge study aims to assess the effect of the Cap TB intervention compared to standard care on the proportion of TB cases diagnosed among children <5 years old.

**Demographic, Clinical, and Laboratory Characteristics and Outcomes of Patients Who Ever Received Etravirine and/or Darunavir:** This is an evaluation to describe the children and adolescents who have received donated product (DRV/ETV). Data from this evaluation will be used as resource by countries as they review national guidelines for second and third line therapies.

**Evaluation of Adolescent Initiative Project Implemented in EGPAF-supported Health Facilities in Homa Bay County:** The aim of this mixed method study is to evaluate the effect of ClIFF-supported ACT Adolescent Project activities on adolescent adherence, retention and viral suppression.

**Evaluation of PMTCT interventions and outcomes among HIV-positive pregnant, breastfeeding women, and their HIV-exposed infants in Homa Bay County:** The overall goal of this evaluation is to determine the relationships between demographic, clinical, and program factors and HIV-related health outcomes for the mother-baby pair in Homa Bay County.

**Women's and health care providers' knowledge and tolerances of risk for HIV treatment during pregnancy:** A qualitative study design aimed at describing views and preferences of women, health care workers and policymakers.

**Evaluation of Advanced HIV Disease in EGPAF Supported Sites in Homa Bay County, Kenya:** Aims to better understand the occurrence of advanced disease among clients.

**Treatment Failure in Supported Facilities in Homa Bay County, Kenya:** With a better understanding of treatment failure, the study should serve as evidence for potential program and policy changes and recommendations.

*The activities described here were made possible by Unitaid, Johnson & Johnson, the United States Agency for International Development, and the generous support of the American people funded by the U.S. Centers for Disease Control and Prevention under the U.S. President's Emergency Plan for AIDS Relief. The content included here is the responsibility of EGPAF and does not necessarily represent the official views of these donors.*

